Heart FailurePhase 3NCT00336336
GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF
A Phase 3 study testing n-3 PUFA and Rosuvastatin in people with Heart Failure, run by Gruppo di Ricerca GISSI at 337 sites in 2 countries.
Trial summary
INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory system have been largely investigated, scanty controlled data are available concerning the role of dietary and metabolic approaches in the management/outcome of patients with heart failure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure
- What is being tested?
- n-3 PUFA and Rosuvastatin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 6,975 participants
- Where
- 337 sitesin 2 countries
- Study dates
- Aug 2002to May 2008
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical evidence of heart failure according to the European Society of Cardiology guidelines (New York Heart Association class II-IV) (32)
- Any left ventricular Ejection Fraction (EF) measured within 3 months from enrolment (if EF% >40%, at least 1 hospital admission for Congestive Heart Failure(CHF) in the previous year)
- No age limits
- Any etiology
- Informed consent (obtained before any study specific procedure)
Who cannot join
- COMMON EXCLUSION CRITERIA (R1=n-3 PUFA vs placebo and R2=rosuvastatin vs placebo):
- Acute Myocardial Infarction, unstable angina or revascularization procedure within 1 month;
- planned cardiac surgery, expected to be performed within 3 months;
- congenital or primary valvular etiology;
- known hypersensitivity to study treatments;
- significant liver disease;
Show all 14Show fewer
- pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception;
- any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol;
- presence of any non-cardiac disease (e.g. cancer) that is likely to significantly shorten life expectancy;
- treatment with any investigational agent within 1 month before randomization;
- patients already on treatment with n-3 PUFA or statin for whom the prescription is confirmed.
- current serum creatinine level >2.5 mg/dL;
- current ALT, AST level >1.5 times the upper normal limit;
- current CPK upper normal limits.
Trial locations and contacts
337 sites in 2 countries.
301 sites in 2 countries
Italy300 sites
Ospedale Civile
Acqui Terme, AL, 15011
Ospedale Civile
Adria, RO, 45011
Ospedale Civile
Agordo, BL, 32021
Ospedale San Giovanni di Dio
Agrigento, AG, 92100
Ospedale Civile San Lazzaro
Alba, CN, 12051
Ospedali Riuniti Albano-Genzano
Albano Laziale, RM, 00041
Presidio Cardiologico G.M. Lancisi
Ancona, AN, 60122
Ospedale Generale Regionale
Aosta, AO, 11100
Ospedale Alto Garda e Ledro
Arco, TN, 38062
Ospedale San Donato
Arezzo, AR, 52100
Osp. Gen.le Prov.le C.G.Mazzoni
Ascoli Piceno, AP, 63100
Ospedale Cardinal Massaia
Asti, AT, 14100
Presidio Ospedaliero Moscati
Aversa, CE, 81031
Ospedale Civile SS.Filippo e Nicola
Avezzano, AQ, 67051
Ospedale Santa Maria Annunziata
Bagno a Ripoli, FI, 50011
Nuovo Pres.Osp. Cutroni Zodda
Barcellona Pozzo di Gotto, ME, 98050
Ospedale San Paolo
Bari, BA, 70123
Ospedale Consorziale Policlinico
Bari, BA, 70124
Ospedale di Venere
Bari - Carbonara, BA, 70012
Ospedale Monsignor Angelo R. di Miccoli
Barletta, BA, 70051
Presidio Ospedaliero S.Maria della Speranza
Battipaglia, SA, 84091
Ospedale Dossetti
Bazzano, BO, 40053
Ospedale Civile
Belluno, BL, 32100
Ospedale di Bentivoglio
Bentivoglio, BO, 40010
Ospedali Riuniti di Bergamo
Bergamo, BG, 24128
Ospedale Policlinico S.Orsola-M.Malpighi
Bologna, BO, 40138
Ospedale Bellaria
Bologna, BO, 40139
Presidio Ospedaliero del Mugello
Borgo San Lorenzo, FI, 50032
Ospedale SS. Trinita'
Borgomanero, 28021
Ospedale Civile di Boscotrecase
Boscotrecase, 80042
Ospedale Civile San Biagio
Bovolone, VR, 37051
Spedali Civili
Brescia, BS, 25123
Osedale A. Businco
Cagliari, CA, 09121
Presidio Ospedaliero SS. Trinita'
Cagliari, CA, 09121
Ospedale Marino
Cagliari, CA, 09126
Azienda Osped. G.Brotzu-S.Michele (S.S.D.coord.Scompenso)
Cagliari, CA, 09134
Azienda Ospedaliera G. Brotzu - S. Michele
Cagliari, CA, 09134
Universita'
Cagliari-Monserrato, CA, 09042
Ospedale Generale Provinciale Gravina
Caltagirone, CT, 95041
Ospedale Santa Maria della Pieta'
Camerino, MC, 62032
Ospedale di Camposampiero
Camposampiero, PD, 35012
Ospedale Barone Lombardo
Canicattì, AG, 92024
Ospedale V. Cosentino
Cariati, CS, 87063
Civico Ospedale Carrara
Carrara, MS, 54033
Ospedale Civile Oglio Po
Casalmaggiore, CR, 26041
Presidio Ospedaliero F. Ferrari
Casarano, LE, 73042
Az. Ospedaliera S.Anna e S.Sebastiano
Caserta, CE, 81100
Azienda Ospedaliera Sant'Anna e San Sebastiano
Caserta, CE, 81100
Fondazione S. Maugeri Clinica del Lavoro
Cassano delle Murge, BA, 70020
Ospedale Santa Scolastica
Cassino, FR, 03043
Opsedale San Leonardo
Castellammare di Stabia, 80053
IRCCS Saverio De Bellis
Castellana Grotte, BA, 70013
Ospedale Civile
Castellaneta, TA, 74011
Ospedale Sant'Anna
Castelnovo ne' Monti, Re, 42035
Ospedale Santa Croce
Castelnuovo Garfagnana, LU, 55032
Ospedale Civile Vittorio Emanuele II
Castelvetrano, TP, 91022
Ospedale San Pellegrino
Castiglione delle Stiviere, MN, 46043
Ospedale Civile Ferrari
Castrovillari, CS, 87012
Ospedale Garibaldi - Nesima
Catania, CT, 95122
Ospedale Garibaldi-Nesima
Catania, CT, 95122
Ospedale Ferrarotto
Catania, CT, 95124
Ospedale Garibaldi - Centro
Catania, CT, 95124
Ospedale Vittorio Emanuele II
Catania, CT, 95124
Ospedale Cannizzaro (U.O.Cardiologia)
Catania, CT, 95126
Ospedle Cannizzaro (UTIC)
Catania, CT, 95126
Azienda Ospedaliera Mater Domini
Catanzaro, CZ, 88100
Ospedale Civile Pugliese
Catanzaro, CZ, 88100
Ospedale Civile Bassa Val di Cecina
Cecina, LI, 57023
Fondazione San Raffaele G. Giglio
Cefalù, PA, 90015
Ospedale Civile Giuseppe Tatarella
Cerignola, FG, 71042
Ospedale di Cernusco sul Naviglio
Cernusco sul Naviglio, MI, 20063
Ospedale M. Bufalini-G. Marconi
Cesena, FC, 47023
Ospedale M.Bufalini-G.Marconi
Cesenatico, FC, 47042
Ospedale Civile Mellini
Chiari, BS, 25032
Ospedale Alta Valle del Tevere
Città di Castello, PG, 06012
Ospedale di Cittadella
Cittadella, PD, 35013
Ospedale Civile San Paolo
Civitavecchia, RM, 00053
Ospedale Generale Zona Parodi Delfino
Colleferro, RM, 00034
Ospedale Generale di Zona Valduce
Como, CO, 22100
Ospedale S. Anna
Como, CO, 22100
Ospedale De Gironcoli
Conegliano Veneto, TV, 31015
Ospedale Santa Maria dei Battuti
Conegliano Veneto, TV, 31015
Ospedale Civile Guido Compagna
Corigliano Calabro, CS, 87064
Ospedale Civile San Sebastiano
Correggio, RE, 42015
Ospedale Valdichiana Santa Margherita
Cortona, AR, 52040
INRCA Istituto Cardiovasculop.Senili
Cosenza, CS, 87100
Ospedale Santissima Annunziata
Cosenza, CS, 87100
Presidio Ospedaliero Mariano Santo
Cosenza, CS, 87100
Villa Maria Cecilia Hospital
Cotignola, RA, 48010
Istituti Ospitalieri di Cremona
Cremona, CR, 26100
Ospedale Civile San Giovanni di Dio
Crotone, KR, 88900
Azienda Ospedaliera
Desenzano del Garda, BS, 25015
Ospedale Civile
Dolo, VE, 30031
Ospedale Civile San Giuseppe
Empoli, FI, 50053
Ospedale Civile Sant'Antonio Abate
Erice, TP, 91016
Ospedale Generale Provinciale
Este, PD, 35042
Ospedale Umberto I
Fasano, BR, 72015
Ospedale Civile Augusto Murri
Fermo, AP, 63023
Arcispedale Sant'Anna
Ferrara, FE, 44100
Ospedale Civile
Fidenza, PR, 43036
Ospedale Santa Maria Nuova
Florence, FI, 50122
Presidio Ospedaliero di Camerata
Florence, FI, 50133
Az. Ospedaliero-Universitaria Careggi
Florence, FI, 50134
Az. Ospedaliero-Universitaria Careggi
Florence, FI, 50139
Az. Ospedaliero-Universitaria Careggi
Florence, FI, 50141
Nuovo Ospedale San Giovanni di Dio
Florence, FI, 50143
Ospedali Riuniti
Foggia, FG, 71100
Nuovo Ospedale San Giovanni Battista
Foligno, PG, 06034
Ospedale G.B.Morgagni-L.Pierantoni
Forlì, FC, 47100
Ospedale del dono Svizzero
Formia, LT, 04023
Ospedale Maggiore SS. Trinita'
Fossano, CN, 12045
Ospedale Civile Dario Camberlingo
Francavilla Fontana, BR, 72021
Ospedale San Sebastiano Martire
Frascati, RM, 00044
Ospedale Civile San Giovanni di Dio
Frattaminore, 80027
Ospedale San Pietro Igneo
Fucecchio, FI, 50054
Ospedale Civile
Gaeta, LT, 04024
Ospedale Santa Caterina Novella
Galatina, LE, 73013
Ospedale S. Antonio Abate
Gallarate, VA, 21013
Ospedale Civile Sacro Cuore di Gesu'
Gallipoli, LE, 73014
Presidio Ospedaliero
Gavardo, BS, 25085
Dimi-Disem
Genova, GE, 16132
Ospedali Civili di Sampierdarena
Genova-Sampierdarena, GE, 16149
Ospedale Padre Antero Micone
Genova-Sestri Ponente, GE, 16153
Ospedale Generale di Zona
Giugliano in Campania, 80014
Ospedale Carlo Borella
Giussano, MI, 20034
Presidio Ospedaliero di Gorizia
Gorizia, GO, 34170
Ospedale della Misericordia
Grosseto, GR, 58100
Ospedale Gubbio-Gualdo Tadino
Gubbio, PG, 06024
Ospedale F. Veneziale
Isernia, IS, 86170
Presidio Ospedaliero San Salvatore
L’Aquila, AQ, 67100
Ospedale S. Andrea
La Spezia, SP, 19124
Ospedale Generale di Zona
Lagonegro, PZ, 85042
Ospedale del Delta
Lagosanto, FE, 44023
Ospedale Renzetti
Lanciano, CH, 66034
Ospedale Civile G. Vietri
Larino, CB, 86035
Ospedale S. Maria Goretti
Latina, LT, 04100
Ospedale Vito Fazzi
Lecce, LE, 73100
Ospedale Umberto I
Lecco, LC, 23900
Ospedale Mater Salutis
Legnago, VR, 37045
Ospedale Civile
Legnano, MI, 20025
Ospedale San Giacomo D'Altopasso
Licata, AG, 92027
Nuovo Ospedale Versilia
Lido di Camaiore, LU, 55043
Ospedali Riuniti
Livorno, LI, 57124
Azienda Ospedaliera Mater Domini
Località Germaneto - Catanzaro, CZ, 88100
Ospedale Civile Simiani
Loiano, BO, 40050
Ospedale di Manerbio
Manerbio, BS, 25025
Ospedale San Camillo De Lellis
Manfredonia, FG, 71043
Presidio Ospedaliero C. Poma
Mantua, MN, 46100
P.O. Marcianese ASL Caserta 1
Marcianise, CE, 81025
A.O. S. Anna-Presidio di Mariano Comense
Mariano Comense, Co, 22066
Ospedale San Giuseppe
Marino, RM, 00047
Presidio Ospedaliero della Valle D'Itria
Martina Franca, TA, 74015
IFC CNR-Ospedale Pasquinucci
Massa, MS, 54100
Ospedale SS.Giacomo e Cristoforo
Massa, MS, 54100
Ospedale S.Andrea-Alta Maremma
Massa Marittima, GR, 58024
Ospedale Madonna delle Grazie
Matera, MT, 75100
Ospedale A. Ajello
Mazara del Vallo, TP, 91026
Ospedale San Martino
Mede, PV, 27035
Ospedale di Menaggio
Menaggio, CO, 22017
Ospedale Generale Provinciale
Merano, BZ, 39012
Ospedale G. Fucito
Mercato San Severino, SA, 84085
Ospedale di Mesoraca
Mesoraca, KR, 88838
Ospedale Papardo
Messina, ME, 98158
Ospedale Civile Umberto I
Mestre, VE, 30171
Ospedale Fatebenefratelli
Milan, MI, 20121
Ospedale Maggiore Policlinico
Milan, MI, 20122
Centro Cardiologico Monzino
Milan, MI, 20138
Ospedale San Paolo
Milan, MI, 20142
Ospedale San Carlo Borromeo
Milan, MI, 20153
Ospedale Niguarda-Villa Marelli
Milan, MI, 20159
Ospedale Niguarda
Milan, MI, 20162
MIOspedale San Raffaele
Milan, 20132
Ospedale Civile
Milazzo, ME, 98057
Ospedale Generale di Zona
Minturno, LT, 04026
Ospedale Civile
Mirano, VE, 30035
Ospedale Policlinico
Modena, MO, 41100
Ospedale Santa Croce
Moncalieri, To, 10024
Presidio Ospedaliero Valdichiana Senese
Montepulciano, SI, 53045
Ospedale di Monterotondo
Monterotondo, RM, 00015
Fondazione S.Maugeri Clinica del Lavoro
Montescano, PV, 27040
Osp.Valdarno "S.Maria della Gruccia"
Montevarchi, AR, 52027
Ospedale San Gerardo
Monza, MI, 20052
Policlinico di Monza
Monza, MI, 20052
Ospedale Civile
Morbegno, SO, 23017
Ospedale Civile Minervini
Mormanno, CS, 87026
Ospedale Umberto I
Mottola, TA, 74017
AORN Cardarelli
Naples, 80131
Azienda Ospedaliera Vincenzo Monaldi
Naples, 80131
Fondazione Pascale
Naples, 80131
Ospedale Domenico Cotugno
Naples, 80131
Policlinico Universitario Federico II
Naples, 80131
Ospedale Sacro Cuore
Negrar, VR, 37024
Ospedale G. Basilotta
Nicosia, EN, 94014
Ospedale Civile
Nocera Inferiore, SA, 84014
Pres.Ospedaliero S. Maria della Pieta'
Nola, 80035
Ospedale Civile
Noventa Vicentina, VI, 36025
Ospedale San Giacomo
Novi Ligure, AL, 15067
Ospedale San Francesco
Nuoro, NU, 08100
Ospedale San Francesco D'Assisi
Oliveto Citra, SA, 84020
Ospedale San Luigi Gonzaga
Orbassano, TO, 10043
Ospedale San Giovanni di Dio
Orbetello, GR, 58015
Ospedale Buccheri La Ferla Fatebenefratelli
Palermo, PA, 90123
A.R.N.A.S. Ospedale Civico e Benfratelli
Palermo, PA, 90127
Ospedale G.F. Ingrassia
Palermo, PA, 90129
Ospedale G.F. Ingrassia
Palermo, PA, 90132
Az. Osp. Villa Sofia CTO (Cardiologia II)
Palermo, PA, 90146
Ospedale V. Cervello
Palermo, PA, 90146
Presidio Ospedaliero Villa Sofia
Palermo, PA, 90146
Ospedale di Ialmicco - Palmanova - Udine
Palmanova, UD, 33057
Ospedale San Francesco di Paola
Paola, CS, 87027
Az. Ospedaliera Universitaria di Parma
Parma, PR, 43100
Centro Osp.Riabilit.Intensiva (CORI)
Passignano sul Trasimeno, PG, 06065
Presidio Ospedaliero di Passirana
Passirana-Rho, MI, 20017
Ospedale Barone Romeo
Patti, ME, 98066
IRCCS - Fondazione Salvatore Maugeri
Pavia, PV, 27100
Ospedale Policlinico San Matteo IRCCS
Pavia, PV, 27100
Presidio Ospedaliero
Pavullo nel Frignano, MO, 41026
Ospedale Civile San Massimo
Penne, PE, 65017
Ospedale Civile dello Spirito Santo
Pescara, PE, 65124
Ospedale M. Chiello
Piazza Armerina, EN, 94015
Ospedale Civile Ave Gratia Plena
Piedimonte Matese, CE, 81016
Ospedale Civile del Cadore
Pieve di Cadore, BL, 32044
Ospedali Destra Secchia
Pieve di Coriano, MN, 46020
Ospedale Civile E. Agnelli
Pinerolo, TO, 10064
Ospedale Villamarina
Piombino, LI, 57025
Presidio Ospedaliero
Poggibonsi, SI, 53034
Ospedale Civile
Policoro, MT, 75025
Azienda Ospedaliera S. Maria degli Angeli
Pordenone, PN, 33170
Ospedale Civile
Portogruaro, VE, 30026
Azienda Ospedaliera San Carlo
Potenza, PZ, 85100
Ospedale Santa Maria delle Grazie
Pozzuoli, 80078
Ospedale Misericordia e Dolce
Prato, PO, 59100
Ospedale Generale Provinciale
Province of Macerata, MC, 62100
Ospedale Santa Maria degli Angeli
Putignano, BA, 70017
Ospedale Civile
Ragusa, RG, 97100
Ospedale M.P. Arezzo
Ragusa, RG, 97100
Policlinico Madonna della Consolazione
Reggio Calabria, RC, 89124
Ospedale G. Ceccarini
Riccione, RN, 47838
P.O. San Camillo De Lellis
Rieti, RI, 02100
Ospedale Infermi
Rimini, RN, 47900
Ospedale Santa Marta
Rivolta d'Adda, CR, 26027
Ospedale Santa Barbara
Rogliano, CS, 87054
Campus Biomedico
Roma, RM, 00128
Ospedale San Filippo Neri
Roma, RM, 00135
Ospedale Sant'Eugenio
Roma, RM, 00144
Ospedale C. Forlanini
Roma, RM, 00149
Ospedale San Camillo
Roma, RM, 00149
Ospedale San Camillo
Roma, RM, 00152
Ospedale Sandro Pertini
Roma, RM, 00157
Policlinico Umberto Primo
Roma, RM, 00161
Ospedale San Carlo di Nancy
Roma, RM, 00165
Presidio Ospedaliero Villa Betania
Roma, RM, 00165
Ospedale Generale di Zona "Cristo Re"
Roma, RM, 00167
Ospedale Fatebenefratelli
Roma, RM, 00168
Policlinico Agostino Gemelli
Roma, RM, 00168
I.N.R.C.A.
Roma, RM, 00189
Ospedale Santo Spirito
Roma, RM, 00193
Ospedale Civile N. Giannettasio
Rossano, CS, 87068
Presidio Ospedaliero
Rovigo, RO, 45100
A.O. S.Giovanni di Dio e Ruggi di Aragona
Salerno, SA, 84131
Ospedale Civile Saluzzo
Saluzzo, CN, 12037
Ospedale Madonna del Soccorso
San Benedetto del Tronto, AP, 63039
Ospedale G. Fra Castoro
San Bonifacio, VR, 37047
Presidio Osped. Pneumologico Galateo
San Cesario di Lecce, LE, 73016
Ospedale S. Antonio
San Daniele del Friuli, UD, 33038
Ospedale Ave Gratia Plena
San Felice A Cancello, CE, 81027
Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, FG, 71013
Ospedale N. Melli
San Pietro Vernotico, BR, 72027
Ospedale Civile
San Vito al Tagliamento, PN, 33078
Presidio Ospedaliero
Sanremo, IM, 18038
P.O. Sant'Agata di Militello
Sant'Agata di Militello, ME, 98076
Ospedale dell'Immacolata
Sapri, SA, 84073
Presidio Ospedaliero
Saronno, VA, 21047
Ospedale San Bartolomeo
Sarzana - Loc. Santa Caterina, SP, 19038
Az. Ospedaliero Universitaria di Sassari
Sassari, SS, 07100
Nuovo Ospedale Civile di Sassuolo
Sassuolo, MO, 41049
Ospedale Civile
Scafati, SA, 84018
Ospedale Scillesi D'America
Scilla, RC, 89024
Ospedale Scillesi D'America
Scilla, RC, 89058
Ospedale Ignazio Veris Delli Ponti
Scorrano, LE, 73020
Ospedale Bolognini
Seriate, BG, 24068
Presidio Gazzaniga c/o Osp. Seriate
Seriate, BG, 24068
Ospedale di Sesto San Giovanni
Sesto San Giovanni, MI, 20099
Ospedale Sestri Levante
Sestri Levante, GE, 16039
Policlinico Santa Maria alle Scotte
Siena, SI, 53100
Ospedale di Circolo A. Bellini
Somma Lombardo, VA, 21019
Ospedale E. Morelli
Sondalo, SO, 23035
Ospedale Civile
Sondrio, SO, 23100
Ospedale Civile SS. Trinita'
Sora, FR, 03039
Presidio Ospedaliero
Soriano Calabro, VV, 89831
Ospedale Santa Maria della Misericordia
Sorrento, 80067
Ospedale A. Angelucci
Subiaco, RM, 00028
Presidio Ospedaliero
Susa, TO, 10059
Azienda Ospedaliera Umberto I
Syracuse, SR, 96100
Presidio Ospedaliero San Vincenzo
Taormina, ME, 98039
Ospedale S. Giuseppe Moscati
Taranto, TA, 74100
Ospedale SS. Annunziata
Taranto, TA, 74100
Ospedale Civile G. Mazzini
Teramo, TE, 64100
Ospedale Pubblico S. Cimino
Termini Imerese, PA, 90018
Ospedale San Timoteo
Termoli, CB, 86039
About this study
Official title: A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure
INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory system have been largely investigated, scanty controlled data are available concerning the role of dietary and metabolic approaches in the management/outcome of patients with heart failure. A large scale, randomized, clinical trial is proposed to test the effects of (a) n-3 PUFA and (b) a lipid lowering agent on top of the best recommended treatments for heart failure.
STUDY DESIGN
Read more
The GISSI-HF is a prospective, multicenter, randomized, double blind, placebo controlled study, with randomized allocation of patients with a clinical diagnosis of heart failure to:
Randomization 1 (R1): n-3 PUFA 1 g daily vs corresponding placebo; Randomization 2 (R2): rosuvastatin 10 mg daily vs corresponding placebo.
OBJECTIVES OF THE STUDY PRIMARY OBJECTIVES
To demonstrate that, in patients with heart failure treated at the best of recommended therapies, long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than the corresponding placebo in the reduction of:
- All-cause mortality
- All-cause mortality or hospitalizations for cardiovascular reason
OTHER END-POINT MEASURES OF EFFICACY
To assess that long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than corresponding placebo in the reduction of:
- Cardiovascular mortality
- Cardiovascular mortality or hospitalizations for any reason
- Sudden cardiac death
- Hospitalizations for any reason
- Hospitalizations for cardiovascular reasons
- Hospitalizations for congestive heart failure
- Myocardial infarction
- Stroke
Read the detailed description
The Protocol is sponsored by an independent organization and partially supported by: AstraZeneca, Società Prodotti antibiotici, Sigma Tau, Pfizer
- Conditions
- Heart Failure
- Being tested
- n-3 PUFA, Rosuvastatin, Placebo
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
n-3 PUFADrug
1 g die per os
RosuvastatinDrug
10 mg die per os
PlaceboDrug
1 gram c. per os
PlaceboDrug
10 mg c. per os
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | N-3PUFA Receives: Drug: n-3 PUFA |
| 2 | Placebo comparator | Not described Receives: Drug: Placebo |
| 3 | Experimental | Rosuvastatin Receives: Drug: Rosuvastatin |
| 4 | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
All-cause mortality
Measured: from enrollment to 1252 deaths in R2 arm
All cause mortality or hospitalizations for any reason
Measured: from enrollment to 1252 deaths
Secondary outcomes (8)
Cardiovascular mortality
Measured: from enrollment to 1252 deaths in R2 arm
Cardiovascular mortality or hospitalization for heart failure or for any reasons
Measured: from enrollment to 1252 deaths in R2 arm
Sudden cardiac death
Measured: from enrollment to 1252 deaths in R2 arm
Hospitalizations for any reasons
Measured: from enrollment to 1252 deaths in R2 arm
Hospitalization for Cardiovascular reasons
Measured: from enrollment to 1252 deaths in R2 arm
Hospitalization for congestive heart failure
Measured: from enrollment to 1252 deaths in R2 arm
Miocardial infarction
Measured: from enrollment to 1252 deaths in R2 arm
Stroke
Measured: from enrollment to 1252 deaths in R2 arm
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2006 (estimated)
- Study startAug 2002
- Primary completionApr 2008
- Study completionMay 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 6,975 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gruppo di Ricerca GISSI
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Luigi Tavazzi, MD, Study chair, Policlinico San Matteo di PaviaGianni Tognoni, MD, Study chair, Consorzio Mario Negri Sud
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00336336
- Sponsor's protocol ID
- G105
- Status last verified
- Sep 2010
- First submitted
- 12 Jun 2006
- Last updated
- 14 Aug 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M; GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004 Aug;6(5):635-41. doi: 10.1016/j.ejheart.2004.03.001.
PubMed 15302013Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1223-30. doi: 10.1016/S0140-6736(08)61239-8. Epub 2008 Aug 29.
PubMed 18757090Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1231-9. doi: 10.1016/S0140-6736(08)61240-4. Epub 2008 Aug 29.
PubMed 18757089Canepa M, Ameri P, Lucci D, Nicolosi GL, Marchioli R, Porcu M, Tognoni G, Franzosi MG, Latini R, Maseri A, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Modes of death and prognostic outliers in chronic heart failure. Am Heart J. 2019 Feb;208:100-109. doi: 10.1016/j.ahj.2018.11.009. Epub 2018 Nov 24.
PubMed 30580128Mantovani A, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. Metabolism. 2018 Jun;83:205-215. doi: 10.1016/j.metabol.2018.02.007. Epub 2018 Mar 29.
PubMed 29477817Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc. 2017 Jul 5;6(7):e005156. doi: 10.1161/JAHA.116.005156.
PubMed 28679559Rossi A, Inciardi RM, Rossi A, Temporelli PL, Lucci D, Gonzini L, Marchioli R, Nicolosi GL, Tavazzi L; GISSI-HF Investigators. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther. 2017 Jun;44:16-23. doi: 10.1016/j.pupt.2017.03.001. Epub 2017 Mar 3.
PubMed 28263812Florea VG, Rector TS, Anand IS, Cohn JN. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial. Circ Heart Fail. 2016 Jul;9(7):e003123. doi: 10.1161/CIRCHEARTFAILURE.116.003123.
PubMed 27413037Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, Proietti G, Barbuzzi S, Nicolosi GL, Tavazzi L, Maggioni AP, Latini R. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail. 2013 Oct;1(5):417-24. doi: 10.1016/j.jchf.2013.05.007. Epub 2013 Sep 11.
PubMed 24621973Barlera S, Tavazzi L, Franzosi MG, Marchioli R, Raimondi E, Masson S, Urso R, Lucci D, Nicolosi GL, Maggioni AP, Tognoni G; GISSI-HF Investigators. Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure trial: proposal for a nomogram. Circ Heart Fail. 2013 Jan;6(1):31-9. doi: 10.1161/CIRCHEARTFAILURE.112.967828. Epub 2012 Nov 14.
PubMed 23152490La Rovere MT, Pinna GD, Maestri R, Barlera S, Bernardinangeli M, Veniani M, Nicolosi GL, Marchioli R, Tavazzi L; GISSI-HF Investigators. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. Eur J Heart Fail. 2012 Dec;14(12):1410-9. doi: 10.1093/eurjhf/hfs126. Epub 2012 Jul 30.
PubMed 22851700Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vardal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012 Sep;14(9):992-9. doi: 10.1093/eurjhf/hfs092. Epub 2012 Jun 27.
PubMed 22740508Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, Cohn JN, Latini R; Valsartan Heart Failure Trial (Val-HeFT) and Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Investigators. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012 Jan 17;125(2):280-8. doi: 10.1161/CIRCULATIONAHA.111.044149. Epub 2011 Dec 2.
PubMed 22139751Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, van Veldhuisen DJ, Montagna L, Cosmi F, Tognoni G, Tavazzi L, Latini R. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011 Nov;32(21):2705-12. doi: 10.1093/eurheartj/ehr190. Epub 2011 Jun 11.
PubMed 21666249Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A, Favero C, Franzosi MG, Serra D, Lucci D, Bianchini F, Bernasconi R, Maggioni AP, Nicolosi G, Porcu M, Tognoni G, Tavazzi L, Marchioli R. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. Am Heart J. 2011 Feb;161(2):338-343.e1. doi: 10.1016/j.ahj.2010.10.032.
PubMed 21315217
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure
- ClinicalTrials.gov ID
- NCT00336336
- Acronym / sponsor ID
- G105
- Conditions
- Heart Failure
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6,975 participants (actual)
- Lead sponsor
- Gruppo di Ricerca GISSIUniversity, hospital or other
- Study start
- Aug 2002
- Primary completion
- Apr 2008 (actual)
- Study completion
- May 2008 (actual)
- First posted
- 13 Jun 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory system have been largely investigated, scanty controlled data are available concerning the role of dietary and metabolic approaches in the management/outcome of patients with heart failure. A large scale, randomized, clinical trial is proposed to test the effects of (a) n-3 PUFA and (b) a lipid lowering agent on top of the best recommended treatments for heart failure.
STUDY DESIGN
The GISSI-HF is a prospective, multicenter, randomized, double blind, placebo controlled study, with randomized allocation of patients with a clinical diagnosis of heart failure to:
Randomization 1 (R1): n-3 PUFA 1 g daily vs corresponding placebo; Randomization 2 (R2): rosuvastatin 10 mg daily vs corresponding placebo.
OBJECTIVES OF THE STUDY PRIMARY OBJECTIVES
To demonstrate that, in patients with heart failure treated at the best of recommended therapies, long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than the corresponding placebo in the reduction of:
- All-cause mortality
- All-cause mortality or hospitalizations for cardiovascular reason
OTHER END-POINT MEASURES OF EFFICACY
To assess that long term administration of (a) n-3 PUFA, (b) rosuvastatin is more effective than corresponding placebo in the reduction of:
- Cardiovascular mortality
- Cardiovascular mortality or hospitalizations for any reason
- Sudden cardiac death
- Hospitalizations for any reason
- Hospitalizations for cardiovascular reasons
- Hospitalizations for congestive heart failure
- Myocardial infarction
- Stroke
Detailed description
The Protocol is sponsored by an independent organization and partially supported by: AstraZeneca, Società Prodotti antibiotici, Sigma Tau, Pfizer
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: n-3 PUFAN-3PUFA |
| 2 | Placebo comparator | Drug: Placebo |
| 3 | Experimental | Drug: RosuvastatinRosuvastatin |
| 4 | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Clinical evidence of heart failure according to the European Society of Cardiology guidelines (New York Heart Association class II-IV) (32)
- Any left ventricular Ejection Fraction (EF) measured within 3 months from enrolment (if EF% >40%, at least 1 hospital admission for Congestive Heart Failure(CHF) in the previous year)
- No age limits
- Any etiology
- Informed consent (obtained before any study specific procedure)
Key exclusion criteria (14 listed)
- Acute Myocardial Infarction, unstable angina or revascularization procedure within 1 month;
- planned cardiac surgery, expected to be performed within 3 months;
- congenital or primary valvular etiology;
- known hypersensitivity to study treatments;
- significant liver disease;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| n-3 PUFA1 g die per os | Drug | 1 |
| Rosuvastatin10 mg die per os | Drug | 3 |
| Placebo1 gram c. per os | Drug | 2 |
| Placebo10 mg c. per os | Drug | 4 |
Primary outcome
All-cause mortality
Time frame: from enrollment to 1252 deaths in R2 arm
All cause mortality or hospitalizations for any reason
Time frame: from enrollment to 1252 deaths
8 secondary outcomes
Cardiovascular mortality
Time frame: from enrollment to 1252 deaths in R2 arm
Cardiovascular mortality or hospitalization for heart failure or for any reasons
Time frame: from enrollment to 1252 deaths in R2 arm
Sudden cardiac death
Time frame: from enrollment to 1252 deaths in R2 arm
Hospitalizations for any reasons
Time frame: from enrollment to 1252 deaths in R2 arm
Hospitalization for Cardiovascular reasons
Time frame: from enrollment to 1252 deaths in R2 arm
Hospitalization for congestive heart failure
Time frame: from enrollment to 1252 deaths in R2 arm
Miocardial infarction
Time frame: from enrollment to 1252 deaths in R2 arm
Stroke
Time frame: from enrollment to 1252 deaths in R2 arm
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2015.
- Background: PubMed 15302013Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M; GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004 Aug;6(5):635-41. doi: 10.1016/j.ejheart.2004.03.001.
- Results publication: PubMed 18757090Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1223-30. doi: 10.1016/S0140-6736(08)61239-8. Epub 2008 Aug 29.
- Results publication: PubMed 18757089Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1231-9. doi: 10.1016/S0140-6736(08)61240-4. Epub 2008 Aug 29.
- Derived from this study: PubMed 30580128Canepa M, Ameri P, Lucci D, Nicolosi GL, Marchioli R, Porcu M, Tognoni G, Franzosi MG, Latini R, Maseri A, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Modes of death and prognostic outliers in chronic heart failure. Am Heart J. 2019 Feb;208:100-109. doi: 10.1016/j.ahj.2018.11.009. Epub 2018 Nov 24.
- Derived from this study: PubMed 29477817Mantovani A, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. Metabolism. 2018 Jun;83:205-215. doi: 10.1016/j.metabol.2018.02.007. Epub 2018 Mar 29.
- Derived from this study: PubMed 28679559Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc. 2017 Jul 5;6(7):e005156. doi: 10.1161/JAHA.116.005156.
- Derived from this study: PubMed 28263812Rossi A, Inciardi RM, Rossi A, Temporelli PL, Lucci D, Gonzini L, Marchioli R, Nicolosi GL, Tavazzi L; GISSI-HF Investigators. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther. 2017 Jun;44:16-23. doi: 10.1016/j.pupt.2017.03.001. Epub 2017 Mar 3.
- Derived from this study: PubMed 27413037Florea VG, Rector TS, Anand IS, Cohn JN. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial. Circ Heart Fail. 2016 Jul;9(7):e003123. doi: 10.1161/CIRCHEARTFAILURE.116.003123.
- Derived from this study: PubMed 24621973Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, Proietti G, Barbuzzi S, Nicolosi GL, Tavazzi L, Maggioni AP, Latini R. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail. 2013 Oct;1(5):417-24. doi: 10.1016/j.jchf.2013.05.007. Epub 2013 Sep 11.
- Derived from this study: PubMed 23152490Barlera S, Tavazzi L, Franzosi MG, Marchioli R, Raimondi E, Masson S, Urso R, Lucci D, Nicolosi GL, Maggioni AP, Tognoni G; GISSI-HF Investigators. Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure trial: proposal for a nomogram. Circ Heart Fail. 2013 Jan;6(1):31-9. doi: 10.1161/CIRCHEARTFAILURE.112.967828. Epub 2012 Nov 14.
- Derived from this study: PubMed 22851700La Rovere MT, Pinna GD, Maestri R, Barlera S, Bernardinangeli M, Veniani M, Nicolosi GL, Marchioli R, Tavazzi L; GISSI-HF Investigators. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. Eur J Heart Fail. 2012 Dec;14(12):1410-9. doi: 10.1093/eurjhf/hfs126. Epub 2012 Jul 30.
- Derived from this study: PubMed 22740508Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vardal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012 Sep;14(9):992-9. doi: 10.1093/eurjhf/hfs092. Epub 2012 Jun 27.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luigi Tavazzi, MD study chair
Policlinico San Matteo di Pavia
Gianni Tognoni, MD study chair
Consorzio Mario Negri Sud
337 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing n-3 PUFA and Rosuvastatin in people with Heart Failure, run by Gruppo di Ricerca GISSI at 337 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 337 sites in Italy, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All-cause mortality (time frame: from enrollment to 1252 deaths in R2 arm). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00336336, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2015.